Gyrodyne, LLC
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
About Gyrodyne, LLC
Opeators of Nonresidential Buildings, SIC 6512
Gyrodyne, LLC manages a real estate portfolio consisting of medical office and industrial properties, while also pursuing land entitlements for these sites. The company leases its developed facilities under agreements where tenants reimburse some or all property operating expenses, including maintenance, utilities, real estate taxes, and insurance. Its primary customers are tenants within the healthcare and industrial sectors, including healthcare service providers and medical institutions such as regional university hospitals.
The company's holdings comprise two primary real estate assets located in New York State. These properties include the Cortlandt Medical Center, spanning 13.8 acres in Westchester County's Cortlandt Manor, and Flowerfield, a 63-acre property in St. James within Suffolk County that features a 14-acre multi-tenant industrial park encompassing 135,000 rentable square feet. The provided text notes that Gyrodyne is organized under the laws of the State of New York, but it does not specify the location of the company's corporate headquarters.
Summary of the business section of Gyrodyne, LLC's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Gyrodyne, LLC
- Headquarters
- St. James, NY
- Address
- 1 Flowerfield, Suite 24 11780
- Phone
- (631) 584-5400
- Website
- gyrodyne.com
- Employees
- 4, Dec 31, 2024
- Industry
- Opeators of Nonresidential Buildings
- Incorporated in
- New York
- Fiscal year ends
- December 31
- Auditor
- Baker Tilly US LLP, Tysons, Virginia
Stock & identifiers
- Ticker
- GYRO
- Exchange
- Nasdaq
- IPO date
- Jul 1, 2015
- Shares outstanding
- 2M, Aug 13, 2026
- Public float
- $6.24M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 11-for-10, Apr 29, 2002
- SEC CIK
- 1589061
- CUSIP
- 403829104
- ISIN
- US4038291047
- LEI
- 549300CF8EE7IDXWHQ23
- EIN
- 46-3838291
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Ronald J. Macklin | Director | 30,441 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2024 | $250.00K | $250.00K | $200.00K | $56 | – |
| FY2023 | $260.00K | $260.00K | $210.00K | $62 | – |
| FY2022 | $260.00K | $260.00K | $210.00K | $50 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2024 and 2023 we had four employees which was reduced to three effective February 28, 2025.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Nov 14, 2024 | Late filing | Notification of late filing |
| Mar 31, 2021 | Late filing | Notification of late filing |
| May 6, 2016 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Nov 17, 2015 | Late filing | Notification of late filing |
| Sep 1, 2015 | Listing | Registration of securities on an exchange (Form 8-A) |
| Jul 1, 2015 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 21, 2013 | Merger | Registration of securities for a merger or exchange offer (S-4) |